Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infusion of third-party mesenchymal stem cells after renal or liver transplantation
2011-001822-81Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Jul 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stem cells in hepatic disease, hepatic failure, hepatocellular carcinoma (HCC) and 8 more, sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoint: Safety of MSC infusion. Started Jul 2011; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
hepatic diseasehepatic failurehepatocellular carcinoma (HCC)fulminant hepatitismetabolic liver disease
Beyond the preview
Go deeper on 2011-001822-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001822-81.